$ATS

ATS Q4 Earnings Call Highlights

ATS (NYSE:ATS) reported fiscal 2026 revenue and adjusted earnings from operations each up about 11%, with Q4 adjusted revenue at CAD 744 million (+3.2%) and adjusted earnings from operations at CAD 76.8 million (+3.4%). Management outlined restructuring to improve margins and cash, including repositioning transportation, expected to remove ~CAD 50 million of dilutive revenue. Q4 order bookings fell 18.4% to CAD 704 million.

Original reporting
Published May 28, 2026, 4:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 28, 2026, 5:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ATS Q4 Earnings Call Highlights — source image
Decision brief

The 30-second read

$ATSBullishMed
01

Why it matters

Key decision points for traders are the fiscal 2027 revenue growth framing (including transportation step-down), the quantified restructuring drag (CAD 28.3M Q4 costs; CAD 5M Q1 charges), and the margin improvement target (50–75 bps) supported by services mix and operating discipline.

02

Market read

Earnings + forward guidance plus restructuring math (dilutive revenue removal, charges, facility sales) can move estimates and positioning into Q1/FY27.

03

What to watch

Transportation revenue step-down could mask underlying softness; also GLP-1 auto-injector backlog declined from prior levels, implying potential lumpiness in future growth.

Relevance 9/10Novelty 7/10Timing: Post-earnings call; sets expectations for Q1 and FY2027 execution.

Background

ATS’ Q4 call emphasized repositioning away from large-scale transportation/automotive projects toward specialized applications, alongside organizational changes to embed services into business units.

Company-level read

Ticker impact

$ATSBullishMedium confidence
Context

ATS reported higher fiscal 2026 revenue/earnings and guided fiscal 2027, while detailing restructuring that removes CAD 50M dilutive transportation revenue.

Expected impact

Moderate positive bias if investors view transportation step-down as non-destructive and margin/cash targets as credible.

Evidence & confidence

The article provides concrete guidance (Q1 revenue range, FY27 modest growth, margin improvement 50–75 bps) and quantified restructuring costs/revenue removal, which can drive estimates and sentiment.

Market effects

Signals continued shift toward higher-margin services/aftermarket and away from lower-return transportation projects in industrial automation/capex equipment.

Tariff commentary suggests limited near-term drag from Canada-to-U.S. trade changes under USMCA/232 updates.

Life sciences and nuclear/radiopharma demand narratives may reinforce investor focus on regulated end-markets and backlog quality.

Counterpoint

Order bookings fell ~18% and book-to-bill is slightly below 1, so revenue growth may rely on backlog conversion rather than fresh demand momentum.

Key entities

  • ATS

    Reported Q4 and fiscal 2026 results; outlined restructuring, facility sales, and fiscal 2027 guidance including margin improvement.

  • Doug Wright

    CEO since January; set priorities around engineering-to-financial conversion, margin, free cash flow, and asset utilization.

Related articles

$ATSMed

ATS Q1 Earnings Call Highlights

ATS said it will consolidate some European facilities and shift technical capabilities to sites with capacity. Management expects the first phase to deliver about CAD 20 million in annualized savings, about 30% of the total fixed-cost program (CAD 60-70 million). Q1 restructuring costs were CAD 5.7 million and non-cash charges CAD 21.5 million. ATS guided Q2 revenue to CAD 660-700 million.

$ATSMed

ATS Reports First Quarter Fiscal 2027 Results and Announces a Fixed Cost Transformation Program

ATS Corporation reported fiscal 2027 first-quarter results for the three months ended June 28, 2026. Revenues were C$693.7 million versus C$736.7 million a year earlier, with a C$0.3 million net loss. Adjusted EBITDA was C$92.9 million. ATS also announced an 18-month Fixed Cost Transformation Program, targeting 15% adjusted earnings from operations margin, with an initial European footprint consolidation and expected C$20 million annual cost reductions.

$ATSMedAI 9/10

ATS (ATS) Q4 2026 Earnings Call Transcript

ATS reported Q4 2026 adjusted revenues of $744 million (+3.2%); organic growth was 1.5% with a 1.7% FX benefit. Q4 adjusted earnings from operations rose 3.4% to $76.8 million; gross margin was 29.4%. Order bookings were $704 million (-18.4%) and backlog about $2 billion. Fiscal 2027 guidance calls for Q1 revenues $700–$740 million and modest full-year growth, with margin improving 50–75 bps.

$ATSMedAI 9/10

ATS Reports Narrower Q4 Loss Due To Higher Revenues, Stock Up

ATS Corporation reported a narrower Q4 2026 net loss for the quarter ended March 31, 2026, citing higher revenues partly offset by higher SG&A. Net loss fell to C$16.2m (from C$68.9m); loss per share to C$0.16 (from C$0.70). Total revenue rose to C$747.1m (from C$574.2m). Outlook for Q1 2027: revenue C$700m–C$740m. Shares closed at $35.27.

$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.